Systemic scleroderma is a complex autoimmune condition that can affect both skin and internal organs, requiring careful monitoring and a personalized approach to care. Understanding the treatment options—from established medications to innovative therapies being explored in clinical research—can help patients and their families navigate this challenging journey.

How Doctors Approach Care: Goals and Treatment Philosophy

When someone receives a diagnosis of systemic scleroderma, also called systemic sclerosis, the journey ahead focuses on managing symptoms, slowing disease progression, and improving quality of life. While there is currently no cure that can stop the overproduction of collagen—the protein that causes tissue hardening and thickening in scleroderma—a range of treatments exists to help control the condition and prevent serious complications.^[1][9]

Treatment plans are highly individualized, depending on the specific form of systemic sclerosis a person has and which organs are affected. The two main patterns are limited disease, where skin thickening is restricted to certain areas like the hands, feet, and face, and diffuse disease, where skin changes extend more widely across the body and internal organs face higher risk of involvement.^[6][8] Because systemic scleroderma can affect the lungs, heart, kidneys, digestive system, and blood vessels, a comprehensive care team typically includes rheumatologists, pulmonologists, cardiologists, gastroenterologists, and other specialists working together.^[3]

The primary goals of treatment are threefold: relieving uncomfortable symptoms such as pain, stiffness, and digestive problems; preventing organ damage through early intervention; and maintaining function in affected parts of the body. Because the disease involves three critical components—immune system dysfunction, blood vessel abnormalities, and tissue scarring (fibrosis)—treatment strategies must address all three areas.^[14]

Early diagnosis and ongoing monitoring are essential. Regular screening tests help doctors detect complications before they become life-threatening. These may include pulmonary function tests to check lung capacity, echocardiography to assess heart and blood vessel pressures, and blood tests to monitor kidney function.^[3] Some patients with severe disease may be candidates for more aggressive interventions, while others with milder forms can manage well with supportive therapies and lifestyle modifications.

Standard Treatment Approaches

Standard treatment for systemic scleroderma involves several categories of medications, each targeting different aspects of the disease. Because the condition varies so much from person to person, healthcare providers tailor medication choices to address the specific organs and symptoms involved in each individual case.^[9]

Managing Blood Vessel Problems and Raynaud’s Phenomenon

Nearly everyone with systemic scleroderma experiences Raynaud’s phenomenon, a condition where blood vessels in the fingers and toes constrict excessively in response to cold or stress, causing color changes—typically white, blue, or red—along with numbness and pain.^[1][8] In severe cases, repeated episodes can lead to painful ulcers or sores on the fingertips, and rarely, tissue damage requiring medical intervention.

To improve blood flow, doctors commonly prescribe calcium channel blockers such as nifedipine or amlodipine, which are blood pressure medications that help dilate constricted blood vessels.^[10][17] These medications work by relaxing the smooth muscle in vessel walls, allowing blood to flow more freely to the extremities. However, they can cause side effects including swelling in the legs and ankles, headaches, and dizziness.

Another class of medications used for Raynaud’s are PDE-5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis), which also improve circulation by relaxing blood vessels.^[10][20] These medications can be particularly helpful for patients who develop digital ulcers. Treatment typically continues long-term, as stopping the medication may allow symptoms to return.

Addressing Immune System Overactivity

Because systemic scleroderma is an autoimmune disease—where the immune system mistakenly attacks the body’s own tissues—medications that suppress immune activity play a central role in treatment.^[2][14] The rationale is that controlling the inflammatory phase of disease can help prevent downstream damage and fibrosis in organs.

Methotrexate is sometimes used, particularly early in the disease course when inflammation in joints or skin is prominent.^[14] This medication requires weekly dosing and regular blood tests to monitor for potential liver or bone marrow effects. Patients taking methotrexate must also avoid alcohol and take folic acid supplements to reduce side effects.

Mycophenolate mofetil (CellCept) has emerged as an important treatment option, particularly for patients with skin involvement and lung disease. Multiple studies have suggested beneficial effects in slowing the progression of skin thickening and preventing worsening of lung fibrosis.^[14][16] The medication requires twice-daily dosing and monitoring for potential side effects including gastrointestinal upset, increased infection risk, and blood count changes.

Cyclophosphamide is a more potent immunosuppressive medication sometimes used for serious lung involvement called interstitial lung disease, where inflammation and scarring affect the lung tissue.^[16] This medication can be given intravenously or by mouth. Because of potentially serious side effects including bladder irritation, hair loss, nausea, and long-term risks to fertility, cyclophosphamide is typically reserved for patients with more severe disease or those who haven’t responded to other treatments.

Treatment duration with immunosuppressive medications varies. Some patients may need only a limited course of therapy if they respond well, while others require ongoing treatment to maintain disease control. Regular blood tests are necessary to monitor for side effects and ensure the medication is working appropriately.

Lung-Specific Treatments

Lung complications are among the most serious concerns in systemic scleroderma. Two main types can occur: interstitial lung disease (ILD), where lung tissue becomes scarred and stiff, and pulmonary arterial hypertension (PAH), where blood pressure in the lung arteries becomes dangerously elevated.

For interstitial lung disease, tocilizumab, a biologic medication that blocks interleukin-6 (a protein involved in inflammation), has been approved to help preserve lung function.^[13][16] Clinical trials showed that while tocilizumab didn’t dramatically improve skin thickening, it did significantly slow the decline in lung capacity. The medication is given as an infusion or injection and requires monitoring for infection risk.

Nintedanib (Ofev), a medication originally developed for other lung diseases, has also been approved for scleroderma-related interstitial lung disease.^[13][16] This oral medication works by blocking multiple signaling pathways involved in lung fibrosis. Common side effects include diarrhea and nausea, which can often be managed with dose adjustments or supportive medications.

For pulmonary arterial hypertension, several medication classes are available. Endothelin receptor antagonists help relax blood vessels in the lungs, while PDE-5 inhibitors improve blood flow. Newer agents such as selexipag and riociguat have further improved outcomes for patients with this serious complication.^[13] Early combination therapy, using multiple medications together, has become the standard approach and has significantly improved survival and quality of life for patients with pulmonary arterial hypertension.

Managing Digestive System Problems

Digestive symptoms are very common in systemic scleroderma and can significantly impact quality of life. The most frequent problem is heartburn and acid reflux, which occur because the muscle connecting the esophagus to the stomach stops working properly, allowing stomach acid to flow backward.^[9][17]

Proton pump inhibitors such as omeprazole, which reduce stomach acid production, are typically prescribed for heartburn.^[17][20] These medications are usually taken once or twice daily before meals and can be used long-term if needed. Some patients also benefit from antacids for breakthrough symptoms.

When the intestines are affected, causing bloating, cramping, constipation, or diarrhea, medications that help move food through the digestive tract may be prescribed. Antibiotics can sometimes help if bacterial overgrowth contributes to symptoms.^[9] Dietary modifications, such as eating smaller, more frequent meals and avoiding foods that trigger symptoms, also play an important supportive role.

Other Symptom Management

Pain management may involve over-the-counter medications like acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) for mild discomfort, though NSAIDs must be used cautiously due to potential kidney and stomach effects.^[9] For more severe pain, prescription pain relievers may be necessary.

Corticosteroids like prednisone are used sparingly in systemic scleroderma because they can increase the risk of a serious kidney complication called scleroderma renal crisis.^[14] However, they may be appropriate for treating specific types of inflammation such as joint inflammation (arthritis) or muscle inflammation (myositis). When used, the lowest effective dose for the shortest possible time is preferred.

Physical and occupational therapy play important supportive roles in maintaining joint mobility, strengthening muscles, and preserving function in daily activities.^[9] Regular exercise, adapted to individual capabilities, helps prevent stiffness and maintain overall health.

Promising Therapies in Clinical Trials

Research into new treatments for systemic scleroderma is advancing rapidly, with numerous innovative approaches being tested in clinical trials. These experimental therapies aim to target the disease more precisely, potentially offering hope for patients who don’t respond well to standard treatments or who have progressive disease despite current medications.

Advanced Immunotherapy Approaches

One of the most exciting developments in scleroderma treatment is CAR T-cell therapy, a sophisticated approach originally developed for cancer treatment. In this therapy, a patient’s own T cells (a type of immune cell) are removed from the blood, genetically modified in the laboratory to recognize and attack specific disease-causing cells, and then returned to the patient’s body.^[15]

KYV-101 is a CD19-directed CAR T-cell therapy being studied specifically for systemic sclerosis. The treatment targets CD19, a protein found on the surface of B cells—immune cells believed to play a key role in driving scleroderma. The therapy aims to deeply deplete these problematic B cells, potentially “resetting” the immune system and halting disease progression.^[15] Early-phase clinical trials (Phase 1/2) are currently enrolling patients with systemic sclerosis, particularly those with more severe or progressive disease that hasn’t responded adequately to standard immunosuppressive treatments. Because this is a highly specialized treatment involving cell modification, it’s only available at select research centers.

Rituximab, while not entirely new, is being studied more extensively in clinical trials for systemic scleroderma. This medication targets the same CD19 protein on B cells but works differently than CAR T therapy—it’s an antibody given by infusion that helps remove B cells from circulation.^[13][16] Multiple trials have shown promising results, with improvement in skin fibrosis and prevention of worsening lung involvement. Rituximab is typically given as a series of infusions, and some patients may need repeat treatments over time to maintain benefits.

Targeting Inflammatory Pathways

Scientists have identified several molecular pathways—sequences of chemical reactions in cells—that contribute to inflammation and fibrosis in scleroderma. New medications are being designed to interrupt these specific pathways.

Agents targeting interferon pathways are under investigation because interferons (proteins that regulate immune responses) appear to be overactive in many scleroderma patients.^[13] By blocking these signals, researchers hope to reduce the inflammatory drive that leads to tissue damage and scarring. These medications are in various phases of clinical testing, from early Phase 1 safety studies to later-phase trials comparing them to standard treatments.

Medications targeting BAFF (B-cell activating factor), a protein that helps B cells survive and function, represent another promising avenue.^[13] By reducing BAFF activity, these drugs aim to decrease the population of overactive B cells contributing to disease. Clinical trials are evaluating whether this approach can improve symptoms and slow progression in systemic sclerosis patients.

Novel Mechanisms to Reduce Fibrosis

Bispecific antibodies—engineered proteins that can simultaneously bind to two different targets—are being developed for scleroderma.^[13] These sophisticated molecules might be able to address multiple disease mechanisms at once, potentially offering more comprehensive disease control than single-target therapies. Early research is exploring various combinations of targets involved in both immune dysfunction and fibrosis formation.

PDE4B inhibitors represent another novel approach. PDE4B is an enzyme involved in inflammatory signaling, and blocking it may reduce the cascade of events leading to tissue scarring.^[13] Early-phase clinical trials are assessing whether these medications can safely reduce skin thickening and other disease manifestations.

Agents targeting melanocortin pathways are also under investigation. The melanocortin system, which plays roles in inflammation and tissue repair, might be dysregulated in scleroderma.^[13] Medications that modulate this system could potentially reduce both inflammation and excessive collagen production.

FcRn inhibitors work by reducing levels of circulating antibodies, including the autoantibodies that contribute to scleroderma.^[13] FcRn is a receptor that helps recycle antibodies in the body, and blocking it leads to faster antibody breakdown. This approach is being tested to see if lowering autoantibody levels can improve disease outcomes.

Stem Cell Transplantation

Autologous hematopoietic stem cell transplantation (auto-HSCT) is a more established but still specialized treatment option for selected patients with severe, rapidly progressive systemic sclerosis.^[13][15] In this procedure, a patient’s own blood-forming stem cells are collected, preserved, and then returned after the patient receives high-dose chemotherapy to suppress the immune system.

The goal is to essentially “reset” the immune system by eliminating the cells driving the autoimmune process and replacing them with healthy stem cells. Clinical trials have shown that auto-HSCT can improve survival and quality of life compared to standard cyclophosphamide treatment in carefully selected high-risk patients.^[15] However, the procedure carries significant risks, including serious infections and treatment-related complications, which is why it’s reserved for patients with severe disease who are otherwise healthy enough to tolerate the intensive process.

Understanding Clinical Trial Phases

Clinical trials proceed through several phases, each designed to answer specific questions about a new treatment. Phase I trials are the first tests in humans and focus primarily on safety—determining what dose can be given safely and what side effects might occur. These studies typically involve small numbers of participants.

Phase II trials expand the testing to more patients and focus on whether the treatment actually works—does it improve symptoms, slow disease progression, or prevent complications? Researchers also continue to monitor safety and side effects in this larger group.

Phase III trials are large comparative studies that test the new treatment against the current standard of care (or sometimes a placebo). These trials provide the definitive evidence needed for regulatory agencies like the FDA to approve a new medication. They may involve hundreds or even thousands of participants across multiple countries.

Accessing Clinical Trials

Clinical trials for systemic sclerosis are being conducted in numerous locations, including major medical centers in the United States, Europe, and other regions. Eligibility criteria vary depending on the specific study but typically include factors such as disease subtype (limited or diffuse), disease duration, extent of organ involvement, and previous treatment history.^[15]

Patients interested in participating in clinical trials should discuss options with their rheumatologist, who can help identify appropriate studies. Trial participation offers potential access to promising new treatments before they become widely available, along with close medical monitoring. However, participants should understand that not all experimental treatments will prove effective, and unknown side effects may emerge.

Most Common Treatment Methods

• Blood Pressure Medications for Circulation
  • Calcium channel blockers like nifedipine and amlodipine to dilate blood vessels and treat Raynaud’s phenomenon
  • PDE-5 inhibitors such as sildenafil and tadalafil to improve blood flow to fingers and toes
  • Medications require long-term use and regular monitoring for side effects
• Immunosuppressive Medications
  • Methotrexate for early disease with joint and skin inflammation
  • Mycophenolate mofetil for skin thickening and lung disease prevention
  • Cyclophosphamide for more severe lung involvement
  • Regular blood tests required to monitor for side effects
• Biologic Therapies
  • Tocilizumab to preserve lung function in interstitial lung disease
  • Rituximab being studied for skin and lung disease improvement
  • Given as infusions or injections with infection risk monitoring
• Anti-Fibrotic Medications
  • Nintedanib approved for slowing lung function decline in scleroderma-related interstitial lung disease
  • Oral medication taken daily with monitoring for digestive side effects
• Pulmonary Arterial Hypertension Treatments
  • Endothelin receptor antagonists to relax lung blood vessels
  • Combination therapy with multiple medications for improved outcomes
  • Newer agents like selexipag and riociguat expanding treatment options
• Digestive System Medications
  • Proton pump inhibitors for heartburn and acid reflux management
  • Prokinetic medications to help move food through the digestive tract
  • Antibiotics when bacterial overgrowth contributes to symptoms
• Advanced Cell Therapies
  • CAR T-cell therapy (KYV-101) targeting CD19 on B cells in clinical trials
  • Autologous hematopoietic stem cell transplantation for severe, progressive disease
  • Available at specialized centers for carefully selected patients
• Physical and Occupational Therapy
  • Exercise programs to maintain joint flexibility and muscle strength
  • Techniques to preserve function in daily activities
  • Skin care strategies to prevent complications